Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,080,486
  • Shares Outstanding, K 181,911
  • Annual Sales, $ 285,140 K
  • Annual Income, $ -518,250 K
  • 60-Month Beta 0.01
  • Price/Sales 28.82
  • Price/Cash Flow N/A
  • Price/Book 6.89
Trade LEGN with:

Options Overview Details

View History
  • Implied Volatility 49.43% ( -1.26%)
  • Historical Volatility 31.66%
  • IV Percentile 48%
  • IV Rank 38.78%
  • IV High 76.23% on 03/07/24
  • IV Low 32.45% on 12/20/23
  • Put/Call Vol Ratio 1.45
  • Today's Volume 152
  • Volume Avg (30-Day) 980
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 22,675
  • Open Int (30-Day) 24,921

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 6
  • High Estimate -0.01
  • Low Estimate -0.75
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.06 +2.13%
on 04/25/24
57.64 -21.93%
on 04/01/24
-10.90 (-19.50%)
since 03/26/24
3-Month
44.06 +2.13%
on 04/25/24
70.13 -35.83%
on 02/27/24
-11.55 (-20.42%)
since 01/26/24
52-Week
44.06 +2.13%
on 04/25/24
77.32 -41.80%
on 07/21/23
-22.95 (-33.77%)
since 04/26/23

Most Recent Stories

More News
Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On

Unsurprisingly, Johnson & Johnson's top investments are all in the healthcare sector.

NVS : 97.68 (-1.39%)
JNJ : 146.45 (-0.25%)
LEGN : 44.98 (+1.26%)
CVRX : 14.62 (+1.60%)
PTGX : 25.19 (+2.15%)
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

/PRNewswire/ -- USA News Group - The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with...

ONC.TO : 1.49 (unch)
GILD : 65.62 (+0.54%)
IMGN : 31.23 (unch)
DAWN : 15.00 (+13.55%)
LEGN : 44.98 (+1.26%)
ONCY : 1.0900 (+0.93%)
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END

ONCY : 1.0900 (+0.93%)
ONC.TO : 1.49 (unch)
GILD : 65.62 (+0.54%)
IMGN : 31.23 (unch)
DAWN : 15.00 (+13.55%)
LEGN : 44.98 (+1.26%)
Promising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meeting

VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already...

ONCY : 1.0900 (+0.93%)
ONC.TO : 1.49 (unch)
GILD : 65.62 (+0.54%)
IMGN : 31.23 (unch)
DAWN : 15.00 (+13.55%)
LEGN : 44.98 (+1.26%)
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today...

LEGN : 44.98 (+1.26%)
Voyager Therapeutics (VYGR) Surges 11.1%: Is This an Indication of Further Gains?

Voyager Therapeutics (VYGR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...

VYGR : 7.59 (+2.29%)
LEGN : 44.98 (+1.26%)
After Jumping 49% in 1 Month, Is It Too Late to Buy Legend Biotech?

Legend's cell therapy seems like it's a winner, but it might be priced in already.

LEGN : 44.98 (+1.26%)
Why Legend Biotech Stock Is Having Its Best Month Yet

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

LEGN : 44.98 (+1.26%)
JNJ : 146.45 (-0.25%)
BMY : 45.21 (+1.14%)
NVS : 97.68 (-1.39%)
BIIB : 210.49 (+3.97%)
ALNY : 145.39 (+1.17%)
MRKR : 4.27 (-2.18%)
Why Shares of Geron Are Up 30% This Week

The company's CEO was scheduled to speak at a virtual conference on Thursday.

LEGN : 44.98 (+1.26%)
JNJ : 146.45 (-0.25%)
GERN : 3.82 (+7.30%)
Legend (LEGN) Stock Up 20% on Data Leak From Blood Cancer Study

Leaked data from Legend Biotech's (LEGN) phase III study of the blood cancer drug, Carvykti, shows a 74% reduction in risk of death or tumor progression. Stock jumps 20% following the news.

BMY : 45.21 (+1.14%)
JNJ : 146.45 (-0.25%)
LEGN : 44.98 (+1.26%)
TSVT : 4.24 (-1.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 46.18
2nd Resistance Point 45.69
1st Resistance Point 45.05
Last Price 44.98
1st Support Level 43.92
2nd Support Level 43.43
3rd Support Level 42.79

See More

52-Week High 77.32
Fibonacci 61.8% 64.61
Fibonacci 50% 60.69
Fibonacci 38.2% 56.77
Last Price 44.98
52-Week Low 44.06

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar